PMC:7172841 / 974-1130 JSONTXT

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T11","span":{"begin":82,"end":93},"obj":"Body_part"}],"attributes":[{"id":"A11","pred":"fma_id","subj":"T11","obj":"http://purl.org/sig/ont/fma/fma62863"}],"text":"abel Tocilizumab treatment of patients was accompanied by increase in circulating lymphocytes. Thus, the unique pattern of immune dysregulation in severe CO"}

{"project":"LitCovid-PD-HP","denotations":[{"id":"T6","span":{"begin":123,"end":143},"obj":"Phenotype"}],"attributes":[{"id":"A6","pred":"hp_id","subj":"T6","obj":"http://purl.obolibrary.org/obo/HP_0002958"}],"text":"abel Tocilizumab treatment of patients was accompanied by increase in circulating lymphocytes. Thus, the unique pattern of immune dysregulation in severe CO"}

{"project":"LitCovid-PMC-OGER-BB","denotations":[{"id":"T35","span":{"begin":5,"end":16},"obj":"DG_35"},{"id":"T36","span":{"begin":70,"end":81},"obj":"CL:0000080"},{"id":"T37","span":{"begin":82,"end":93},"obj":"CL:0000542"},{"id":"T38","span":{"begin":123,"end":129},"obj":"UBERON:0002405"},{"id":"T39","span":{"begin":130,"end":143},"obj":"GO:0065007"},{"id":"T10312","span":{"begin":5,"end":16},"obj":"DG_35"},{"id":"T74668","span":{"begin":70,"end":81},"obj":"CL:0000080"},{"id":"T90672","span":{"begin":82,"end":93},"obj":"CL:0000542"},{"id":"T2958","span":{"begin":123,"end":129},"obj":"UBERON:0002405"},{"id":"T86620","span":{"begin":130,"end":143},"obj":"GO:0065007"}],"text":"abel Tocilizumab treatment of patients was accompanied by increase in circulating lymphocytes. Thus, the unique pattern of immune dysregulation in severe CO"}

{"project":"LitCovid-PubTator","denotations":[{"id":"48","span":{"begin":30,"end":38},"obj":"Species"},{"id":"52","span":{"begin":5,"end":16},"obj":"Chemical"}],"attributes":[{"id":"A48","pred":"tao:has_database_id","subj":"48","obj":"Tax:9606"},{"id":"A52","pred":"tao:has_database_id","subj":"52","obj":"MESH:C502936"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"abel Tocilizumab treatment of patients was accompanied by increase in circulating lymphocytes. Thus, the unique pattern of immune dysregulation in severe CO"}